Michael Pourdehnad, MD

Hematologist
Oncologist

Dr. Michael Pourdehnad is a hematologist-oncologist who specializes in cancers that originate in blood-forming tissues or immune system cells. He also has expertise in noncancerous disorders of the blood.

Pourdehnad is a physician-scientist, a medical doctor who devotes much time to research. In addition to treating patients, he is dedicated to developing novel therapies for cancer patients with especially challenging cases. In this capacity, he also works with the biotechnology company Celgene to translate research discoveries into new treatments for blood cancers.

After earning his medical degree from Chicago Medical School at Rosalind Franklin University School of Medicine and Science, Pourdehnad completed a residency in internal medicine at Icahn School of Medicine at Mount Sinai, where he served as chief resident. He then completed a fellowship in adult hematologic malignancies and blood and marrow transplantation at UCSF.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave., 4th Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
Fax: (415) 353-2467

Hours: Monday to Friday
8 a.m. – 5 p.m

Board Certification

Internal Medicine, American Board of Internal Medicine

More about Michael Pourdehnad

Education

Chicago Medical School at Rosalind Franklin University School of Medicine and Science 2005

Residencies

Icahn School of Medicine at Mount Sinai, Internal Medicine 2008

Fellowships

UCSF, Adult Hematologic Malignancies and Blood and Marrow Transplantation 2012

Selected Research and Publications

  1. Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, Raymon H, Narla RK, Barnes L, Khambatta G, Chiu H, Kosek J, Kang J, Amantangelo MD, Waldman M, Lopez-Girona A, Cai T, Pourdehnad M, Trotter M, Daniel TO, Schafer PH, Klippel A, Thakurta A, Chopra R, Gandhi AK. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015 Aug 06; 126(6):779-89.
  2. Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):11988-93.
  3. Cunningham JT, Pourdehnad M, Stumpf CR, Ruggero D. Investigating Myc-dependent translational regulation in normal and cancer cells. Methods Mol Biol. 2013; 1012:201-12.
  4. Pourdehnad M, Basu S, Duarte P, Okpaku AS, Saboury B, Hustinx R, Alavi A. Reduced grey matter metabolism due to white matter edema allows optimal assessment of brain tumors on 18F-FDG-PET. Hell J Nucl Med. 2011 Sep-Dec; 14(3):219-23.
  5. Newberg AB, Saffer J, Farrar J, Pourdehnad M, Alavi A. Stability of cerebral blood flow measures using a split-dose technique with (99m)Tc-exametazime SPECT. Nucl Med Commun. 2005 May; 26(5):475-8.
  6. Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging. 2005 Jul; 32(7):749-56.
  7. Hustinx R, Pourdehnad M, Kaschten B, Alavi A. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am. 2005 Jan; 43(1):35-47.
  8. Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol. 2004 May; 68(1):1-9.
  9. Schmitz A, Shiue CY, Feng Q, Shiue GG, Deng S, Pourdehnad MT, Schirrmacher R, Vatamaniuk M, Doliba N, Matschinsky F, Wolf B, Rösch F, Naji A, Alavi AA. Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents. Nucl Med Biol. 2004 May; 31(4):483-91.
  10. Newberg A, Pourdehnad M, Alavi A, d'Aquili EG. Cerebral blood flow during meditative prayer: preliminary findings and methodological issues. Percept Mot Skills. 2003 Oct; 97(2):625-30.
  11. Zhuang HM, Cortés-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martínez-Lázaro R, Lee JH, Loman JC, Rossman MD, Alavi A. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun. 2001 Oct; 22(10):1123-8.
  12. Meyer PT, Cortés-Blanco A, Pourdehnad M, Levy-Reis I, Desiderio L, Jang S, Alavi A. Inter-modality comparisons of seizure focus lateralization in complex partial seizures. Eur J Nucl Med. 2001 Oct; 28(10):1529-40.
  13. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, Mozley PD, Rossman MD, Albelda SM, Alavi A. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001 Sep; 42(9):1412-7.
  14. Zhuang H, Yamamoto AJ, Sinha P, Pourdehnad M, Liu Y, Alavi A. Similar pelvic abnormalities on FDG positron emission tomography of different origins. Clin Nucl Med. 2001 Jun; 26(6):515-7.
  15. Zhuang H, Pourdehnad M, Yamamoto AJ, Rossman MD, Alavi A. Intense F-18 fluorodeoxyglucose uptake caused by mycobacterium avium intracellulare infection. Clin Nucl Med. 2001 May; 26(5):458.
  16. Newberg A, Alavi A, Baime M, Pourdehnad M, Santanna J, d'Aquili E. The measurement of regional cerebral blood flow during the complex cognitive task of meditation: a preliminary SPECT study. Psychiatry Res. 2001 Apr 10; 106(2):113-22.
  17. Zhuang H, Duarte PS, Pourdehnad M, Maes A, Van Acker F, Shnier D, Garino JP, Fitzgerald RH, Alavi A. The promising role of 18F-FDG PET in detecting infected lower limb prosthesis implants. J Nucl Med. 2001 Jan; 42(1):44-8.
  18. Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun. 2000 Sep; 21(9):793-8.
  19. Zhuang HM, Duarte P, Pourdehnad M, Yamamoto AJ, Loman JC, Sinha P, Alavi A. 26. Incidental findings should be included in the analysis of cost-effectiveness for evaluation of pulmonary nodules by FDG-PET. Clin Positron Imaging. 2000 Jul; 3(4):180.
  20. Couturier O, Le Rest C, Gournay J, Pourdehnad M, Bridji B, Turzo A, Bizais Y. Gastric emptying of solids: estimates of lag phase and constant emptying times. Nucl Med Commun. 2000 Jul; 21(7):665-75.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.